Panacea Biotec Limited

357.7

INR
+17.00(+4.99%)
As of November 14, 2024 10:00:00 AM

About Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc for the manufacture and supply of Azacitidine injection; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
3.54x
Operating MarginLast 12 months
-16.35
+0% quarterly YoY
Market Cap
1933.68 CrINR
Employees
1936
CEO
NA
Website

Panacea Biotec Limited

357.7

INR
+17.00(+4.99%)
As of November 14, 2024 10:00:00 AM

About Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc for the manufacture and supply of Azacitidine injection; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
3.54x
Operating MarginLast 12 months
-16.35
+0% quarterly YoY
Market Cap
1933.68 CrINR
Employees
1936
CEO
NA
Website